Dibenzylamine--a novel blocker of the voltage-dependent K+ current in myocardial mouse cells.
B Doepner, R Koopmann, A Knopp, H Hirche, K Benndorf
Index: Naunyn Schmiedebergs Arch. Pharmacol. 364(1) , 9-13, (2001)
Full Text: HTML
Abstract
Ventricular myocytes of the mouse ventricle were voltage clamped with a patch-clamp technique in the whole-cell configuration. At depolarizing voltage pulses, these myocytes develop a large voltage-dependent K+ outward current. Application of the drug dibenzylamine (DBA) to the bath solution blocked the voltage-dependent K+ current. The concentration/response relationship for the peak current at +40 mV indicates a 1:1 binding of the drug to the receptor with a concentration of half maximum effect of 43.1 micromol/l. The block did not require activation of the channels by depolarizing pulses. At concentrations causing partial block (25 micromol/l), the block was independent of voltage. At the same concentration, DBA completely blocked the slow component of the recovery from inactivation (-80 mV) whereas steady-state inactivation was not altered. It is concluded that DBA is a novel blocker of the voltage-dependent K+ current in mouse cardiac myocytes which preferentially affects the current component generating the slow recovery from inactivation.
Related Compounds
Related Articles:
2002-08-15
[Anal. Biochem. 307(2) , 316-21, (2002)]
2012-10-07
[Org. Biomol. Chem. 10(37) , 7536-44, (2012)]
1994-11-01
[Food Chem. Toxicol. 32(11) , 1015-9, (1994)]
2003-11-24
[J. Pharm. Biomed. Anal. 33(4) , 775-82, (2003)]
2010-09-15
[Bioorg. Med. Chem. Lett. 20(18) , 5544-7, (2010)]